Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Tenapanor in Healthy Volunteers
NCT02819687Phase 1Completed
- Sponsor
- Ardelyx
- Start
- Nov 2010
- Primary completion
- Mar 2011
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tenapanor in irritable bowel syndrome (IBS) and hyperphosphatemia (11 arms), sponsored by Ardelyx. Primary endpoint: Adverse events at 7 days. Started Nov 2010; status: completed.
02
Drugs
tenapanor
03
Conditions
irritable bowel syndrome (IBS)hyperphosphatemia
Beyond the preview
Go deeper on NCT02819687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819687.